CORDIS
EU research results

CORDIS

English EN

NEURAL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH PARKINSON’S DISEASE

Objective

There are currently no cures for Parkinson's disease (PD) but one of the most effective reparative therapies in patients to date has been with allotransplants of dopamine (DA) neuroblasts obtained from fetal ventral mesencephalic (VM) tissue. However, this cell transplantation approach has given inconsistent results, with some patients doing extremely well and coming off anti-PD medication for years, whilst others have shown no or only modest clinical improvements, and in some cases also developed severe, off-state graft-induced dyskinesias (GIDs). The reasons behind this heterogeneity of outcomes, and the emergence of GIDs in particular, need to be better understood, not least in the perspective of the rapid advances that are now being made in the development of stem-cell based therapies. There is therefore an urgent need to revisit the trials that have already been done with fetal VM tissue in PD patients, with the expectation that a critical reassessment can form the basis for an optimised and more standardised procedure that will translate into more consistently efficacious transplants with minimal side-effects. Over the last two years a group of international experts, including the key investigators of the previous European and North American trials, has been re-examining the outcome of these trials as well as reviewing the results obtained from recent and ongoing animal experimental studies, and identified a number of weaknesses that may explain the inconsistent outcome in previous trials. As a result of these discussions, the group has agreed to join forces in a new round of experimental work and cell therapy trials in PD, based on a new jointly developed protocol where all these factors are taken into account. In the first instance fetal VM tissue containing mesencephalic DA neuroblasts will be used, with the expectation that this will pave the way for bigger trials using dopaminergic neurons derived from stem cells.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Address

Trinity Lane The Old Schools
Cb2 1tn Cambridge

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 3 808 371,15

Administrative Contact

Renata Schaeffer (Mr.)

Participants (14)

Sort alphabetically

Sort by EU Contribution

Expand all

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 982 706,24

CARDIFF UNIVERSITY

United Kingdom

EU Contribution

€ 1 114 980

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 636 024,40

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 369 600

UNIVERSITAETSKLINIKUM FREIBURG

Germany

EU Contribution

€ 2 005 726

LIFE SCIENCE GOVERNANCE INSTITUTE

Austria

EU Contribution

€ 213 664,98

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 756 201

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 25 849,30

DANDO WEISS & COLUCCI LIMITED

United Kingdom

EU Contribution

€ 310 162,14

LIFE TECHNOLOGIES LIMITED

United Kingdom

EU Contribution

€ 173 600

Inomed Medizintechnik GmbH

Germany

EU Contribution

€ 73 800

Cambridge Cognition LTD

United Kingdom

EU Contribution

€ 61 650

SKANE LANS LANDSTING

Sweden

EU Contribution

€ 671 759,99

IMANOVA LIMITED

United Kingdom

EU Contribution

€ 789 999,80

Project information

Grant agreement ID: 242003

Status

Closed project

  • Start date

    1 January 2010

  • End date

    30 June 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 16 142 794,19

  • EU contribution

    € 11 994 095

Coordinated by:

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom